New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.

Abstract

The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data… (More)
DOI: 10.1158/1078-0432.CCR-09-1947

Topics

1 Figure or Table

Slides referencing similar topics